Commercialization of cell therapies – biopreservation’s make or break impact: an interview with Mike Rice
Mike Rice, CEO of NASDAQ traded BioLifeSolutions (WA, USA) explains the importance of biopreservation in commercializing regenerative medicine therapies and why funding for new cell-based therapies remains high.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.